Intellia Therapeutics Inc
NASDAQ:NTLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
US |
|
Discovery Harbour Resources Corp
XTSX:DHR
|
CA |
|
Silex Systems Ltd
ASX:SLX
|
AU |
|
Impinj Inc
NASDAQ:PI
|
US |
|
Valartis Group AG
SIX:VLRT
|
CH |
|
Arm Holdings PLC
NASDAQ:ARM
|
UK |
|
Oppenheimer Holdings Inc
NYSE:OPY
|
US |
|
STINAG Stuttgart Invest AG
F:STG
|
DE |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
Lumax AutoTechnologies Ltd
NSE:LUMAXTECH
|
IN |
|
Ritchie Bros Auctioneers Inc
TSX:RBA
|
CA |
|
A
|
AirAsia Indonesia Tbk PT
IDX:CMPP
|
ID |
Wall Street
Price Targets
NTLA Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
NTLA
is 25.16 USD
with a low forecast of 5.05 USD and a high forecast of 111.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NTLA's stock price target?
Price Target
25.16
USD
According to Wall Street analysts, the average 1-year price target for
NTLA
is 25.16 USD
with a low forecast of 5.05 USD and a high forecast of 111.3 USD.
What is Intellia Therapeutics Inc's Revenue forecast?
Projected CAGR
42%
For the last 10 years the
compound annual growth rate for
Intellia Therapeutics Inc's revenue is
27%.
The projected
CAGR
for the next 3 years is
42%.
